Department of Pathology, Boston Children's Hospital and Harvard Medical School, Boston, MA, USA.
Department of Molecular Biotechnology and Health Sciences, Molecular Biotechnology Center, University of Torino, Torino, Italy.
Mol Oncol. 2023 Nov;17(11):2215-2217. doi: 10.1002/1878-0261.13547. Epub 2023 Oct 31.
The development of tailored therapies designed to specifically target driver oncogenes has initiated a revolutionary era in cancer biology. The availability of a growing number of selective inhibitors has generated novel experimental and clinical paradigms. These represent an opportunity and a challenge for researchers and clinicians to delve deeper into the intricate dynamics of cancer development and response to treatment. By directly inhibiting key driver oncogenes involved in tumor initiation and progression, scientists have an unprecedented opportunity to conduct longitudinal and clonal evolutionary studies of how cancer cells adapt, rewire, and exploit conflictive or overlapping signaling dependencies in response to treatment in vitro and in vivo. This challenge has to be progressively resolved to discover more effective and personalized cancer therapies.
针对驱动致癌基因的靶向治疗方法的发展，开创了癌症生物学的新纪元。越来越多的选择性抑制剂的出现，产生了新的实验和临床范例。这为研究人员和临床医生提供了一个机会和挑战，让他们深入研究癌症发展和对治疗反应的复杂动态。通过直接抑制肿瘤起始和进展中涉及的关键驱动致癌基因，科学家们有机会以前所未有的方式进行纵向和克隆进化研究，了解癌细胞如何适应、重新布线以及在体外和体内对治疗做出反应时利用冲突或重叠的信号依赖性。为了发现更有效和个性化的癌症治疗方法，这个挑战必须逐步得到解决。
